Oregon Health & Science University

Extracellular Vesicles & Cell-Free RNAs Conference 2023: Advancing Biological Research - Latest Innovations in EV/Exosomes Explored (Laguna Hills, CA - November 28-30, 2023)

Retrieved on: 
Lundi, juillet 24, 2023
University, Asia Pacific Advanced Network, Exhibition, Anesthesiology, Research, Oregon Health & Science University, University of Kansas, University of Washington, Beer, Personalized medicine, Therapy, Translational Genomics Research Institute, Biology, EVS, National Cancer Institute, Seminal vesicles, Assistant professor, National Football Foundation Distinguished American Award, Speaker, Perioperative medicine, Laboratory, NIH, Conference, Wine, Vaccine, Management, Pathology, Chemistry

DUBLIN, July 24, 2023 /PRNewswire/ -- The "Extracellular Vesicles & Cell-Free RNAs 2023" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 24, 2023 /PRNewswire/ -- The "Extracellular Vesicles & Cell-Free RNAs 2023" conference has been added to ResearchAndMarkets.com's offering.
  • Welcome to the Extracellular Vesicles & Cell-Free RNAs: Technologies Driving Biological Investigations 2023 Conference to be held in-person on-site in beautiful Laguna Hills, California.
  • Bringing together researchers and industry participants from both academia and industry, this established event, will discuss the latest innovations and developments in EV/Exosomes fields from a Technology Development and Utilization Perspective.
  • There is an Extensive International Perspective at this Conference with Speakers, Poster Presenters, Sponsors, and Exhibitors from the US, Europe, and Asia/Pacific.

Skanska signs additional contract to expand hospital in Portland, USA, for USD 91M, about SEK 1.0 billion

Retrieved on: 
Lundi, juillet 10, 2023
Skanska, Hospital, Patient, Oregon Health & Science University, Plaster

STOCKHOLM, July 10, 2023 /PRNewswire/ -- Skanska has signed a contract amendment with Oregon Health & Science University for its Hospital Expansion Project in Portland, Oregon, USA.

Key Points: 
  • STOCKHOLM, July 10, 2023 /PRNewswire/ -- Skanska has signed a contract amendment with Oregon Health & Science University for its Hospital Expansion Project in Portland, Oregon, USA.
  • The contract amendment is worth USD 91M, about SEK 1.0 billion, which will be included in the US order bookings for the second quarter of 2023.
  • The new contract includes exterior framing and cladding, roofing, fireproofing, patient lifts, long lead electrical and mechanical equipment for the new hospital expansion building.
  • Construction of the approximately 50,000-square meter, 14 story hospital expansion began in 2022 and is expected to open to patients in 2026.

The Inner Circle Acknowledges, Bradley Hester as a Top Pinnacle Professional for his contributions to the Dentistry Field

Retrieved on: 
Mercredi, juillet 5, 2023
Dentistry, Bachelor of Science in Nursing, University, Oral medicine, Most valuable player, IV, Education, Volunteers in Medicine, Anxiety, University of Portland, Fear, Oregon Health & Science University, Temporomandibular joint dysfunction, Sleep apnea, Private practice, Volunteering, Multimedia, TMJ, Inner circle, High, Oregon Health & Science University School of Dentistry, International Congress of Oral Implantologists, Patient, Aesthetics, Dog, Dental, Diagnosis, Mouth, Nursing, Science, Central Oregon, Medicine

BEND, Ore., July 5, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Bradley Hester is acknowledged as a Top Pinnacle Professional for his contributions to the Dentistry Field.

Key Points: 
  • BEND, Ore., July 5, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Bradley Hester is acknowledged as a Top Pinnacle Professional for his contributions to the Dentistry Field.
  • Dr. Hester was called to the field of dentistry when he was in 7th grade and began his educational journey at the University of Portland.
  • He earned a Bachelor of Science degree; won a scholarship to play baseball; and was voted Most Valuable Player.
  • A highlight of his higher education experience, the doctor also achieved the Highest Batting Average award during his senior season.

Minutia, Oregon Health & Sciences University and Go Pen Win First-Ever American Diabetes Association Innovation Challenge

Retrieved on: 
Dimanche, juin 25, 2023
CGM, Insulin, American Diabetes Association, Oregon Health & Science University, Diabetes, LAUNCH (Innovation Challenge), Gestational diabetes, Woman, Innovation, T2DM, School, Type 1, Work, SAN, Faculty of Allied Health Sciences, University of Peradeniya, ADA, The Leona M. and Harry B. Helmsley Charitable Trust, Disease, Pharmaceutical industry, Medical device, Chionanthus

SAN DIEGO, June 24, 2023 /PRNewswire/ -- Today, the American Diabetes Association® (ADA) announced the winner of its inaugural pitch competition at the 83rd Scientific Sessions of the American Diabetes Association (ADA) in San Diego, CA. The first-ever Innovation Challenge highlighted six business concepts for diabetes care before a panel of potential funders, with the goal of connecting innovators and startup companies with transformative solutions and ideas. The winners, Minutia, Oregon Health & Sciences University and Go Pen presented three unique and impactful solutions to a variety of diabetes challenges.  

Key Points: 
  • SAN DIEGO, June 24, 2023 /PRNewswire/ -- Today, the American Diabetes Association® (ADA) announced the winner of its inaugural pitch competition at the 83rd Scientific Sessions of the American Diabetes Association (ADA) in San Diego, CA.
  • The first-ever Innovation Challenge highlighted six business concepts for diabetes care before a panel of potential funders, with the goal of connecting innovators and startup companies with transformative solutions and ideas.
  • The winners, Minutia, Oregon Health & Sciences University and Go Pen presented three unique and impactful solutions to a variety of diabetes challenges.
  • Winner: Oregon Health & Sciences University – Distal and proximal interventions that occur across all systems including healthcare, social services, home/neighborhoods, schools, employers, and communities all to improve diabetes outcomes.

Cartesian Therapeutics Announces Landmark Study in The Lancet Neurology of First Successful Clinical Trial of RNA Cell Therapy in Autoimmunity

Retrieved on: 
Jeudi, juin 22, 2023
Research, Neurology, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, University, Therapy, Lancet Neurology, Phase II, Neurotoxicity, Efficacy, Immunoglobulin therapy, Clinical trial, Bone marrow, Oregon Health & Science University, NIH, Chapel Hill, DRS, University of South Florida, Myasthenia gravis, RNA, Autoimmunity, University of Miami, Bangladesh Technical Education Board, CAR, DSM-IV codes, National Institute of Neurological Disorders and Stroke, Cytokine release syndrome, MG, Patient, Physician, Northwestern Health Sciences University, Autotransplantation, NINDS, Paper, Toxic encephalopathy, American Neurological Association, Immunosuppression, Myasthenia, The Lancet, Lancet, Safety, Pharmaceutical industry, Vaccine, Stroke, Cartesian

Cartesian Therapeutics , a clinical-stage biotechnology company pioneering cell therapies for autoimmune diseases, announced today the publication of a landmark paper in The Lancet Neurology.

Key Points: 
  • Cartesian Therapeutics , a clinical-stage biotechnology company pioneering cell therapies for autoimmune diseases, announced today the publication of a landmark paper in The Lancet Neurology.
  • The study describes Descartes-08, a cutting-edge RNA CAR-T (rCAR-T) therapy administered to patients with generalized myasthenia gravis (MG), a debilitating autoimmune neurological disease.
  • This is the first clinical trial using rCAR-T to treat autoimmunity, and the first successful Phase 2 trial using an engineered cell therapy to treat autoimmunity.
  • Clinical benefit was sustained long-term for most patients, even months after completing the course of therapy.

Neurona Therapeutics Presents One-Year Data on the First Patient Treated with NRTX-1001 Cell Therapy in an Ongoing Phase I/II Trial for Drug-resistant Focal Epilepsy

Retrieved on: 
Jeudi, juin 15, 2023
Cognition, Seizure, State University of New York Upstate Medical University, ISSCR, Clinical trial, DSM-IV codes, Deficit spending, History, Dementia, Oregon Health and Science University Center for Women's Health, Patient, Risk, SAN, SUNY Downstate Health Sciences University, International Society, Annual general meeting, Phase, FDA, Therapy, Memory, Oregon Health & Science University, Caregiver, Pharmaceutical industry

SAN FRANCISCO, June 15, 2023 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders, announced the presentation of new data from the open-label, single arm, starting dose-level of its ongoing Phase I/II clinical trial of a one-time dose of NRTX-1001 in people with drug-resistant mesial temporal lobe epilepsy (MTLE). The preliminary data demonstrate promising reduction (>90%) in seizure frequency in the first and second patients at one year and seven-months post-treatment, respectively. In addition, neuropsychological testing suggests an improvement in memory after NRTX-1001 administration. These preliminary clinical observations, as well as supporting preclinical data, are being presented at the Annual Meeting of the International Society for Stem Cell Research (ISSCR) which is being held June 14 - 17 in Boston, MA and virtually.

Key Points: 
  • The preliminary data demonstrate promising reduction (>90%) in seizure frequency in the first and second patients at one year and seven-months post-treatment, respectively.
  • In addition, neuropsychological testing suggests an improvement in memory after NRTX-1001 administration.
  • Both patients continue to report reduced overall seizure counts of >90% at one year- and seven-months post NRTX-1001 administration, respectively.
  • A second oral presentation at the meeting presented by Catherine Priest, Ph.D., Neurona’s chief development officer, detailed the preclinical and translational data supporting the Phase I/II clinical trial of NRTX-1001.

Quality initiative reduces unnecessary IV antihypertensive use for patients with severely elevated blood pressure

Retrieved on: 
Jeudi, juin 15, 2023
IV, Prevalence, Oregon Health & Science University, Hypertension, New York City Department of Health and Mental Hygiene, NPO, Quality, Acute kidney injury, Hospital, BP, Editorial, Hospital medicine, MD, Patient, Patient safety, EHR, Division, SUNY Downstate Health Sciences University, Myocardial injury after non-cardiac surgery, Mouth, Pharmaceutical industry, Medical device, Medicine

Management with one-time doses of intravenous (IV) antihypertensives may increase adverse events such as acute kidney injury, myocardial injury or low blood pressure.

Key Points: 
  • Management with one-time doses of intravenous (IV) antihypertensives may increase adverse events such as acute kidney injury, myocardial injury or low blood pressure.
  • Findings showed for ED-only encounters, IV hydralazine orders had a 49.5% reduction, IV labetalol orders a 30.1% reduction, and aggregate IV hydralazine and IV labetalol orders a 38.7% reduction.
  • For inpatient encounters, IV hydralazine had a 22% reduction, IV labetalol orders a 6.3% reduction, and aggregate IV hydralazine and IV labetalol orders a 13.4% reduction.
  • “By reducing unnecessary antihypertensive IV use, this low effort intervention likely had an impact on decreasing adverse events."

ESO Releases Groundbreaking Research on Disparities in Prehospital Pain Management for Long Bone Fractures

Retrieved on: 
Jeudi, juin 1, 2023
Software, Mobile, Wireless, General Health, Data Management, Law Enforcement, Emergency Services, Technology, Hospitals, Health Technology, Nursing, Practice Management, Health, Public Policy, Government, Oregon Institute of Technology, Science, Operational definition, ESO, Centers for Disease Control and Prevention, Humerus, Oregon Health & Science University, Record, Research, Patient, Doctor of Philosophy, EMS, Oregon Health and Science University Center for Women's Health, Hospital, Data, SUNY Downstate Health Sciences University, Emergency medical services, Fracture, Femur, Pain, Magnetic resonance, Racism, Safety, Medical imaging, Black, White

This groundbreaking research uses data from the ESO Data Collaborative, one of the nation's largest integrated healthcare research databases, inclusive of EMS data and linked hospital outcomes.

Key Points: 
  • This groundbreaking research uses data from the ESO Data Collaborative, one of the nation's largest integrated healthcare research databases, inclusive of EMS data and linked hospital outcomes.
  • The findings are based on more than 35,000 patients with long bone fractures transported by 400 EMS agencies between January 1, 2019, and December 31, 2020.
  • "Inadequate pain management in prehospital emergency care persists, and this burden is experienced to a greater extent among Black patients," said Dr. Remle Crowe, Director of Clinical and Operational Research at ESO.
  • According to the ESO Data Collaborative, EMS administered pain medication to 72% of White patients with severe pain compared to just 59% of Black patients with severe pain.

Eugene, Oregon Plastic Surgeon Dr. Kiya Movassaghi, Internationally Recognized Expert in Breast Surgery, Elected as President-Elect of The Aesthetic Society

Retrieved on: 
Mercredi, mai 31, 2023
Medical school, Research, Former, Oregon Health & Science University, Patient, SUNY Downstate Health Sciences University, Executive Committee, School, Plastic, Health, Safety, Clinical, Dentistry, Breast, Medicine

EUGENE, Ore., May 31, 2023 /PRNewswire/ -- Dr. Kiya Movassaghi, Founder and Director of Movassaghi Plastic Surgery & Ziba Medical Spa in Eugene, Oregon, was recently chosen by his colleagues to be President-Elect of The Aesthetic Society for 2023. The Aesthetic Society is the world's leading organization devoted solely to aesthetic plastic surgery. As President-Elect of the Aesthetic Society, Dr. Movassaghi will uphold the organization's primary missions, including promoting excellence in aesthetic plastic surgery and cosmetic medicine by fostering education, research, and innovation, as well as promoting increased safety.

Key Points: 
  • The Aesthetic Society is the world's leading organization devoted solely to aesthetic plastic surgery.
  • As President-Elect of the Aesthetic Society, Dr. Movassaghi will uphold the organization's primary missions, including promoting excellence in aesthetic plastic surgery and cosmetic medicine by fostering education, research, and innovation, as well as promoting increased safety.
  • He has also demonstrated his commitment to the plastic surgery community as Former President of the Northwest Society of Plastic Surgeons, and in previous leadership positions within The Aesthetic Society.
  • "I believe that The Aesthetic Society is vital to the professional development of plastic surgeons worldwide," says Dr. Movassaghi.

Global Stem Cell Research Leader, CHA Medical & Bio Group Expands Its Global Presence With Launch of Anti-Aging Research Institute in Los Angeles, Ca.

Retrieved on: 
Jeudi, mai 25, 2023
Health, Stem Cells, Genetics, Research, Science, Pharmaceutical, Biotechnology, GMP, CHA, Embryonic stem cell, Rejuvenation, HLA, Oregon Health & Science University, Gene editing, Clinical trial, Cha University, Multimedia, History, Cerebral palsy, Food and Drug Administration, Regeneration, CDMO, Patent, OHSU, Stem cell, School of Life Sciences (University of Dundee), Epithelium, SCNT, International Student Congress Of (bio)Medical Sciences, Food, Vaccine

CHA Medical & Bio Group, a global leader in stem cell research based in South Korea, announced its plan to establish the CHA Power Aging Research Translational Institute (CHA PARTI) in Los Angeles.

Key Points: 
  • CHA Medical & Bio Group, a global leader in stem cell research based in South Korea, announced its plan to establish the CHA Power Aging Research Translational Institute (CHA PARTI) in Los Angeles.
  • In 2014, CHA Medical & Bio Group established the first-ever cloned stem cell lines using adult somatic stem cells.
  • (Graphic: Business Wire)
    CHA PARTI, a collaborative research institute involving CHA Biotech, CHA University, and CHA Medical & Bio Group is scheduled to open later this year.
  • CHA Medical & Bio Group has been at the forefront of stem cell research and gained global recognition for these innovative efforts.